JAK Inhibitors Show Promise in Fighting PsA Symptoms and Progression
A 2021 study brought promising news for PsA patients. It showed that JAK inhibitors can reduce symptom severity and slow disease progression. These small molecule drugs, unlike biologics, target the immune system directly. Two JAK inhibitors, tofacitinib and upadacitinib, are FDA-approved for PsA treatment.
JAK inhibitors work by suppressing the immune system, which can lead to side effects like increased infection risk, particularly for upper respiratory infections. Common side effects include nausea, headaches, and changes in cholesterol levels. Serious side effects may involve abnormal blood counts, liver function tests, bowel perforation, and decreased kidney function.
A 2022 review found little difference between biologics and JAK inhibitors in terms of safety and side effects. However, JAK inhibitors are a newer treatment option, offering targeted therapy for autoimmune disorders like PsA. The FDA has approved several drugs for PsA, including the JAK inhibitor tofacitinib, bimekizumab, golimumab, and the biosimilar flixabi.
JAK inhibitors have shown potential in reducing PsA symptoms and slowing progression. However, like any medication, they carry risks, including serious side effects. Patients and healthcare providers must weigh benefits and risks. Further research is needed to fully understand their long-term effects.
